Review

perindopril (MedChemExpress)

Name: perindopril
Brand: MedChemExpress
Rating: 93 (10 reviews)

MedChemExpress is a verified supplier

MedChemExpress manufactures this product

About

News

Press Release

Team

Advisors

Partners

Contact

Bioz Stars

Bioz vStars

Buy from Supplier

Structured Review

MedChemExpress perindopril

The longer-term effects of p.o delivered SPION-RLX or SPION-B7-33 vs the ACE inhibitor, <t>perindopril,</t> on measures of LV fibrosis, hypertrophy an vascular rarefaction in mice with cardiomyopathy, when administered from days 14–42 post-injury. A Shown is the mean ± SEM systolic blood pressure (SBP) for saline-injected, ISO-injected and ISO-injected + perindopril-treated mice (from n = 7 mice per group) at day 14 (prior to perindopril treatment) and day 42 (after 4-weeks of perindopril treatment). B Perl’s Prussian Blue staining of iron within the LV and liver of SPION-RLX- or B7-33-treated mice indicated that SPION-RLX or SPION-B7-33 was able to reach the target site (LV) and liver after 4-weeks of administration to ISO-injured mice. C Representative images of picrosirius red-stained LV tissue sections show the extent of interstitial collagen deposition within the LV midzone in each of the groups investigated. D – F Also shown are the mean ± SEM D %interstitial LV collagen deposition (fibrosis) per field and E LV TGF-β1 levels per field. F Representative picrosirius red-stained images also show the extent of LV cardiomyocyte size in each of the groups investigated. G The mean ± SEM LV cardiomyocyte cross sectional area in each of the groups analysed was then determined. H Representative immunohistochemically-stained sections for α-smooth muscle actin (SMA) show the extent of α-SMA-stained blood vessel density in each of the groups investigated. I Also shown is the mean ± SEM LV blood vessel density per group analysed. The data presented in panels D , E , G and I were obtained from n = 6–7 mice per group. The white coloured circles in each of the bar plots represent the individual data points per group. ** p < 0.01, *** p < 0.001 vs the saline group; # p < 0.05, ## p < 0.01, ### p < 0.001 vs the ISO group; § p < 0.05, §§§ p < 0.001 vs the ISO + RLX-treated group; ¶ p < 0.05, ¶¶¶ p < 0.001 vs the ISO + Empty-SPION-treated group; + p < 0.05 vs the ISO + Perindoril-treated group

Perindopril, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 93/100, based on 10 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/perindopril/product/MedChemExpress
Average 93 stars, based on 10 article reviews

perindopril - by Bioz Stars, 2026-02

93/100 stars

Images

1) Product Images from "Immune cell uptake of glycinated nanoparticles conjugated to anti-fibrotic peptides enables their prolonged activity and oral administration"

Article Title: Immune cell uptake of glycinated nanoparticles conjugated to anti-fibrotic peptides enables their prolonged activity and oral administration

Journal: Journal of Biomedical Science

doi: 10.1186/s12929-025-01198-8

The longer-term effects of p.o delivered SPION-RLX or SPION-B7-33 vs the ACE inhibitor, perindopril, on measures of LV fibrosis, hypertrophy an vascular rarefaction in mice with cardiomyopathy, when administered from days 14–42 post-injury. A Shown is the mean ± SEM systolic blood pressure (SBP) for saline-injected, ISO-injected and ISO-injected + perindopril-treated mice (from n = 7 mice per group) at day 14 (prior to perindopril treatment) and day 42 (after 4-weeks of perindopril treatment). B Perl’s Prussian Blue staining of iron within the LV and liver of SPION-RLX- or B7-33-treated mice indicated that SPION-RLX or SPION-B7-33 was able to reach the target site (LV) and liver after 4-weeks of administration to ISO-injured mice. C Representative images of picrosirius red-stained LV tissue sections show the extent of interstitial collagen deposition within the LV midzone in each of the groups investigated. D – F Also shown are the mean ± SEM D %interstitial LV collagen deposition (fibrosis) per field and E LV TGF-β1 levels per field. F Representative picrosirius red-stained images also show the extent of LV cardiomyocyte size in each of the groups investigated. G The mean ± SEM LV cardiomyocyte cross sectional area in each of the groups analysed was then determined. H Representative immunohistochemically-stained sections for α-smooth muscle actin (SMA) show the extent of α-SMA-stained blood vessel density in each of the groups investigated. I Also shown is the mean ± SEM LV blood vessel density per group analysed. The data presented in panels D , E , G and I were obtained from n = 6–7 mice per group. The white coloured circles in each of the bar plots represent the individual data points per group. ** p < 0.01, *** p < 0.001 vs the saline group; # p < 0.05, ## p < 0.01, ### p < 0.001 vs the ISO group; § p < 0.05, §§§ p < 0.001 vs the ISO + RLX-treated group; ¶ p < 0.05, ¶¶¶ p < 0.001 vs the ISO + Empty-SPION-treated group; + p < 0.05 vs the ISO + Perindoril-treated group

Figure Legend Snippet: The longer-term effects of p.o delivered SPION-RLX or SPION-B7-33 vs the ACE inhibitor, perindopril, on measures of LV fibrosis, hypertrophy an vascular rarefaction in mice with cardiomyopathy, when administered from days 14–42 post-injury. A Shown is the mean ± SEM systolic blood pressure (SBP) for saline-injected, ISO-injected and ISO-injected + perindopril-treated mice (from n = 7 mice per group) at day 14 (prior to perindopril treatment) and day 42 (after 4-weeks of perindopril treatment). B Perl’s Prussian Blue staining of iron within the LV and liver of SPION-RLX- or B7-33-treated mice indicated that SPION-RLX or SPION-B7-33 was able to reach the target site (LV) and liver after 4-weeks of administration to ISO-injured mice. C Representative images of picrosirius red-stained LV tissue sections show the extent of interstitial collagen deposition within the LV midzone in each of the groups investigated. D – F Also shown are the mean ± SEM D %interstitial LV collagen deposition (fibrosis) per field and E LV TGF-β1 levels per field. F Representative picrosirius red-stained images also show the extent of LV cardiomyocyte size in each of the groups investigated. G The mean ± SEM LV cardiomyocyte cross sectional area in each of the groups analysed was then determined. H Representative immunohistochemically-stained sections for α-smooth muscle actin (SMA) show the extent of α-SMA-stained blood vessel density in each of the groups investigated. I Also shown is the mean ± SEM LV blood vessel density per group analysed. The data presented in panels D , E , G and I were obtained from n = 6–7 mice per group. The white coloured circles in each of the bar plots represent the individual data points per group. ** p < 0.01, *** p < 0.001 vs the saline group; # p < 0.05, ## p < 0.01, ### p < 0.001 vs the ISO group; § p < 0.05, §§§ p < 0.001 vs the ISO + RLX-treated group; ¶ p < 0.05, ¶¶¶ p < 0.001 vs the ISO + Empty-SPION-treated group; + p < 0.05 vs the ISO + Perindoril-treated group

Techniques Used: Saline, Injection, Staining

Image Search Results

Journal: Journal of Biomedical Science

Article Title: Immune cell uptake of glycinated nanoparticles conjugated to anti-fibrotic peptides enables their prolonged activity and oral administration

doi: 10.1186/s12929-025-01198-8

Figure Lengend Snippet: The longer-term effects of p.o delivered SPION-RLX or SPION-B7-33 vs the ACE inhibitor, perindopril, on measures of LV fibrosis, hypertrophy an vascular rarefaction in mice with cardiomyopathy, when administered from days 14–42 post-injury. A Shown is the mean ± SEM systolic blood pressure (SBP) for saline-injected, ISO-injected and ISO-injected + perindopril-treated mice (from n = 7 mice per group) at day 14 (prior to perindopril treatment) and day 42 (after 4-weeks of perindopril treatment). B Perl’s Prussian Blue staining of iron within the LV and liver of SPION-RLX- or B7-33-treated mice indicated that SPION-RLX or SPION-B7-33 was able to reach the target site (LV) and liver after 4-weeks of administration to ISO-injured mice. C Representative images of picrosirius red-stained LV tissue sections show the extent of interstitial collagen deposition within the LV midzone in each of the groups investigated. D – F Also shown are the mean ± SEM D %interstitial LV collagen deposition (fibrosis) per field and E LV TGF-β1 levels per field. F Representative picrosirius red-stained images also show the extent of LV cardiomyocyte size in each of the groups investigated. G The mean ± SEM LV cardiomyocyte cross sectional area in each of the groups analysed was then determined. H Representative immunohistochemically-stained sections for α-smooth muscle actin (SMA) show the extent of α-SMA-stained blood vessel density in each of the groups investigated. I Also shown is the mean ± SEM LV blood vessel density per group analysed. The data presented in panels D , E , G and I were obtained from n = 6–7 mice per group. The white coloured circles in each of the bar plots represent the individual data points per group. ** p < 0.01, *** p < 0.001 vs the saline group; # p < 0.05, ## p < 0.01, ### p < 0.001 vs the ISO group; § p < 0.05, §§§ p < 0.001 vs the ISO + RLX-treated group; ¶ p < 0.05, ¶¶¶ p < 0.001 vs the ISO + Empty-SPION-treated group; + p < 0.05 vs the ISO + Perindoril-treated group

Article Snippet: Perindopril was purchased from MedChemExpress (Monmouth Junction, NJ, USA).

Techniques: Saline, Injection, Staining

Figure 1. Effect of the different treatments on the daily food intake throughout the whole study (mean ± SD). a Significant compared to the control group; b Significant relative to the un- treated methotrexate group; c Significant relative to methotrexate group treated with perindopril 0.5 mg/kg/day; d Significant relative to methotrexate group treated with perindopril 1 mg/kg/day. MTX: methotrexate; PNP: perindopril.

Journal: Pharmaceuticals

Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

doi: 10.3390/ph18030358

Figure Lengend Snippet: Figure 1. Effect of the different treatments on the daily food intake throughout the whole study (mean ± SD). a Significant compared to the control group; b Significant relative to the un- treated methotrexate group; c Significant relative to methotrexate group treated with perindopril 0.5 mg/kg/day; d Significant relative to methotrexate group treated with perindopril 1 mg/kg/day. MTX: methotrexate; PNP: perindopril.

Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

Techniques: Control

Figure 2. Effect of the different doses of perindopril on the liver function tests in the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; ALT: alanine transaminase; AST: aspartate transaminase; ALP: alkaline phosphatase.

Journal: Pharmaceuticals

Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

doi: 10.3390/ph18030358

Figure Lengend Snippet: Figure 2. Effect of the different doses of perindopril on the liver function tests in the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; ALT: alanine transaminase; AST: aspartate transaminase; ALP: alkaline phosphatase.

Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

Techniques:

Figure 3. Effect of the different doses of perindopril on the redox status of the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; MDA: malondialdehyde; SOD: superoxide dismutase; TAC: total antioxidant capacity.

Journal: Pharmaceuticals

Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

doi: 10.3390/ph18030358

Figure Lengend Snippet: Figure 3. Effect of the different doses of perindopril on the redox status of the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; MDA: malondialdehyde; SOD: superoxide dismutase; TAC: total antioxidant capacity.

Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

Techniques:

Figure 4. Effect of the different doses of perindopril on sirtuin-1 and peroxisome proliferator- activated receptor gamma levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; SIRT1: sirtuin-1; PPAR-γ: peroxisome proliferator-activated receptor gamma.

Journal: Pharmaceuticals

Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

doi: 10.3390/ph18030358

Figure Lengend Snippet: Figure 4. Effect of the different doses of perindopril on sirtuin-1 and peroxisome proliferator- activated receptor gamma levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; SIRT1: sirtuin-1; PPAR-γ: peroxisome proliferator-activated receptor gamma.

Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

Techniques:

Figure 5. Effect of the different doses of perindopril on KEAP1, Nrf2, and HO-1 content of the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; KEAP1: Kelch-like ECH-associated protein 1; Nrf2: nuclear factor erythroid 2-related factor 2; HO-1: heme oxygenase-1.

Journal: Pharmaceuticals

Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

doi: 10.3390/ph18030358

Figure Lengend Snippet: Figure 5. Effect of the different doses of perindopril on KEAP1, Nrf2, and HO-1 content of the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; KEAP1: Kelch-like ECH-associated protein 1; Nrf2: nuclear factor erythroid 2-related factor 2; HO-1: heme oxygenase-1.

Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

Techniques:

Figure 5 shows the effect of the different treatments on KEAP1/Nrf2/HO-1 signaling in the hepatic tissues. The significant increase in tissue KEAP1 levels associated with the significant decline in the hepatic tissue content of Nrf2 and HO-1 induced by methotrexate injection was dose-dependently mitigated with the administration of perindopril. This clarifies the role played by KEAP1 in the regulation of Nrf2/HO-1 signaling.

Journal: Pharmaceuticals

Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

doi: 10.3390/ph18030358

Figure Lengend Snippet: Figure 5 shows the effect of the different treatments on KEAP1/Nrf2/HO-1 signaling in the hepatic tissues. The significant increase in tissue KEAP1 levels associated with the significant decline in the hepatic tissue content of Nrf2 and HO-1 induced by methotrexate injection was dose-dependently mitigated with the administration of perindopril. This clarifies the role played by KEAP1 in the regulation of Nrf2/HO-1 signaling.

Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

Techniques: Injection

Figure 6. Effect of the different doses of perindopril on IL-1β, IL-6, MCP-1, and TNF-α levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); *** = p < 0.001; MTX: methotrexate; PNP: perindopril; IL-1β: interleukin 1-beta; MCP-1: monocyte chemoattractant protein 1; TNF-α: tumor necrosis factor-alpha.

Journal: Pharmaceuticals

Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

doi: 10.3390/ph18030358

Figure Lengend Snippet: Figure 6. Effect of the different doses of perindopril on IL-1β, IL-6, MCP-1, and TNF-α levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); *** = p < 0.001; MTX: methotrexate; PNP: perindopril; IL-1β: interleukin 1-beta; MCP-1: monocyte chemoattractant protein 1; TNF-α: tumor necrosis factor-alpha.

Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

Techniques:

Figure 7. Effect of the different doses of perindopril on HMGB1/RAGE/NF-κB axis in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non-significant, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; HMGB1: High-Mobility Group Box 1; RAGE: receptors for advanced glycation end products; NF-κB: nuclear factor kappa B.

Journal: Pharmaceuticals

Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

doi: 10.3390/ph18030358

Figure Lengend Snippet: Figure 7. Effect of the different doses of perindopril on HMGB1/RAGE/NF-κB axis in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non-significant, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; HMGB1: High-Mobility Group Box 1; RAGE: receptors for advanced glycation end products; NF-κB: nuclear factor kappa B.

Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

Techniques:

Figure 8. Effect of the different doses of perindopril on phospho-mTOR, total AMPK, and LC3-II levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non- significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; phospho- mTOR: phosphorylated mammalian target of rapamycin; AMPK: adenosine monophosphate- activated protein kinase; LC3-II: microtubule-associated protein light chain 3.

Journal: Pharmaceuticals

Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

doi: 10.3390/ph18030358

Figure Lengend Snippet: Figure 8. Effect of the different doses of perindopril on phospho-mTOR, total AMPK, and LC3-II levels in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non- significant, * = p < 0.05, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; phospho- mTOR: phosphorylated mammalian target of rapamycin; AMPK: adenosine monophosphate- activated protein kinase; LC3-II: microtubule-associated protein light chain 3.

Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

Techniques:

Figure 9. Effect of the different doses of perindopril on hydroxyproline, MMP-3, and MMP-9 in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non-significant, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; MMP: matrix metalloproteinase.

Journal: Pharmaceuticals

Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

doi: 10.3390/ph18030358

Figure Lengend Snippet: Figure 9. Effect of the different doses of perindopril on hydroxyproline, MMP-3, and MMP-9 in the hepatic tissues of the animal groups treated with methotrexate (mean ± SD); ns = non-significant, ** = p < 0.01, *** = p < 0.001; MTX: methotrexate; PNP: perindopril; MMP: matrix metalloproteinase.

Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

Techniques:

Figure 10. Hematoxylin and eosin-stained sections of the liver from (A) the control group showing the characteristic hexagonal classic hepatic lobules with central veins (CV) at the center and portal tracts (PT) at the periphery. The polygonal hepatocytes are arranged in cords separated by blood sinusoids (S) (×100); (B) methotrexate group exhibiting loss of normal hepatic architecture with dilated and markedly congested central vein (CV) and portal venules (PV) with diffuse perivascular, periportal, and interstitial inflammatory cellular infiltration (I). The central parts of the blood sinusoids (S) appear dilated in some regions with focal areas of hepatic necrosis (Thin arrows) (×100); (C) Portal tract of methotrexate group showing dilated congested portal venules (PV) and hepatic arterioles (HA) with proliferation of bile ductules (BD) (Thick arrows). Also, scattered areas of inflammatory cellular infiltration (I) are seen in the portal area (×400); (D) methotrexate group treated with a small dose of perindopril revealing a significant improvement in the hepatic architecture with cords of normal hepatocytes that surround a mildly dilated central vein (CV). Some hepatic sinusoids appear mildly dilated (S) with scanty areas of hepatic necrosis (Thin arrows) and inflammatory cellular infiltration (I) (×100); (E) methotrexate group treated with a moderate dose of perindopril showing minimal dilatation of the central veins which are surrounded by cords of hepatocytes with acidophilic cytoplasm and vesicular nuclei. Some of the blood sinusoids (S) appear dilated with minimal inflammatory cellular infiltration (I) (×100); (F) methotrexate group treated with a large dose of perindopril exhibiting restoration of the normal hepatic histomorphic structure with appearance of the classic hexagonal hepatic lobules with apparently normal central veins (CV) and portal tracts with minimal congestion of the portal venules (PV) (×100).

Journal: Pharmaceuticals

Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

doi: 10.3390/ph18030358

Figure Lengend Snippet: Figure 10. Hematoxylin and eosin-stained sections of the liver from (A) the control group showing the characteristic hexagonal classic hepatic lobules with central veins (CV) at the center and portal tracts (PT) at the periphery. The polygonal hepatocytes are arranged in cords separated by blood sinusoids (S) (×100); (B) methotrexate group exhibiting loss of normal hepatic architecture with dilated and markedly congested central vein (CV) and portal venules (PV) with diffuse perivascular, periportal, and interstitial inflammatory cellular infiltration (I). The central parts of the blood sinusoids (S) appear dilated in some regions with focal areas of hepatic necrosis (Thin arrows) (×100); (C) Portal tract of methotrexate group showing dilated congested portal venules (PV) and hepatic arterioles (HA) with proliferation of bile ductules (BD) (Thick arrows). Also, scattered areas of inflammatory cellular infiltration (I) are seen in the portal area (×400); (D) methotrexate group treated with a small dose of perindopril revealing a significant improvement in the hepatic architecture with cords of normal hepatocytes that surround a mildly dilated central vein (CV). Some hepatic sinusoids appear mildly dilated (S) with scanty areas of hepatic necrosis (Thin arrows) and inflammatory cellular infiltration (I) (×100); (E) methotrexate group treated with a moderate dose of perindopril showing minimal dilatation of the central veins which are surrounded by cords of hepatocytes with acidophilic cytoplasm and vesicular nuclei. Some of the blood sinusoids (S) appear dilated with minimal inflammatory cellular infiltration (I) (×100); (F) methotrexate group treated with a large dose of perindopril exhibiting restoration of the normal hepatic histomorphic structure with appearance of the classic hexagonal hepatic lobules with apparently normal central veins (CV) and portal tracts with minimal congestion of the portal venules (PV) (×100).

Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

Techniques: Staining, Control

Figure 11. Hepatic tissue sections of immunohistochemical staining of cleaved caspase 3 in (A) The control group clarifying minimal positive immunostaining for cleaved caspase 3; (B) The group that received methotrexate alone exhibiting strongly positive immunostaining for cleaved caspase 3; (C–E) Methotrexate-injected groups treated with small, moderate, and large doses of perindopril, respectively, showing mild positive immunostaining for cleaved caspase 3; (F) Quantitative represen- tation of the percentage of cleaved caspase 3 immune expression in the different studied groups (% of the control); * = p < 0.05, *** = p < 0.001; MTX: methotrexate; PNP: perindopril.

Journal: Pharmaceuticals

Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

doi: 10.3390/ph18030358

Figure Lengend Snippet: Figure 11. Hepatic tissue sections of immunohistochemical staining of cleaved caspase 3 in (A) The control group clarifying minimal positive immunostaining for cleaved caspase 3; (B) The group that received methotrexate alone exhibiting strongly positive immunostaining for cleaved caspase 3; (C–E) Methotrexate-injected groups treated with small, moderate, and large doses of perindopril, respectively, showing mild positive immunostaining for cleaved caspase 3; (F) Quantitative represen- tation of the percentage of cleaved caspase 3 immune expression in the different studied groups (% of the control); * = p < 0.05, *** = p < 0.001; MTX: methotrexate; PNP: perindopril.

Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

Techniques: Immunohistochemical staining, Staining, Control, Immunostaining, Injection, Expressing

Figure 12. Electron micrographs of ultrathin sections in the liver from animals of (A) the control group showing normal architecture of the hepatic tissues. The nuclei (N) appeared spherical with regular outlines with a small amount of heterochromatin in the peripheral regions and a large central amount of euchromatin and prominent nucleolus. The cytoplasm of the hepatocytes contains abundant mitochondria (Arrow) with well-developed cristae and the rough endoplasmic reticulum (RER) consists of closely packed parallel and flattened cisternae (Arrowhead); (B,C) methotrexate- treated group showing shrunken irregular nucleus with dispersed chromatin (N) and reduced number of the mitochondria with disrupted cristae (Arrow). The cisternae of the rough endoplasmic reticulum (RER) of the hepatocytes are fragmented (Arrowhead) with extensive fat droplets (F) and marked cytoplasmic vacuolation (V); (D) methotrexate group treated with a small dose of perindopril revealing irregular nucleus with preserved nucleolus (N). There is a mild increase in the number of the viable mitochondria with mild disrupted cristae (Arrow), partly preserved cisternae of the rough endoplasmic reticulum (Arrowhead), and small number of fat droplets could be observed (F); (E) methotrexate group treated with a moderate dose of perindopril exhibiting a spherical nucleus with regular wall and preserved nucleolus (N). There is moderate increase in the number of the mitochondria with mild disrupted cristae (Arrow) with mild disruption and wide separation of the cisternae of the rough endoplasmic reticulum (Arrowhead); (F) methotrexate group treated with a large dose of perindopril showing a normal spherical nucleus with intact regular walls and preserved nucleolus (N). The mitochondria are abundant with preserved cristae (Arrow) and the rough endoplasmic reticulum cisternae appear nearly normal with mild dilatation (Arrowhead).

Journal: Pharmaceuticals

Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

doi: 10.3390/ph18030358

Figure Lengend Snippet: Figure 12. Electron micrographs of ultrathin sections in the liver from animals of (A) the control group showing normal architecture of the hepatic tissues. The nuclei (N) appeared spherical with regular outlines with a small amount of heterochromatin in the peripheral regions and a large central amount of euchromatin and prominent nucleolus. The cytoplasm of the hepatocytes contains abundant mitochondria (Arrow) with well-developed cristae and the rough endoplasmic reticulum (RER) consists of closely packed parallel and flattened cisternae (Arrowhead); (B,C) methotrexate- treated group showing shrunken irregular nucleus with dispersed chromatin (N) and reduced number of the mitochondria with disrupted cristae (Arrow). The cisternae of the rough endoplasmic reticulum (RER) of the hepatocytes are fragmented (Arrowhead) with extensive fat droplets (F) and marked cytoplasmic vacuolation (V); (D) methotrexate group treated with a small dose of perindopril revealing irregular nucleus with preserved nucleolus (N). There is a mild increase in the number of the viable mitochondria with mild disrupted cristae (Arrow), partly preserved cisternae of the rough endoplasmic reticulum (Arrowhead), and small number of fat droplets could be observed (F); (E) methotrexate group treated with a moderate dose of perindopril exhibiting a spherical nucleus with regular wall and preserved nucleolus (N). There is moderate increase in the number of the mitochondria with mild disrupted cristae (Arrow) with mild disruption and wide separation of the cisternae of the rough endoplasmic reticulum (Arrowhead); (F) methotrexate group treated with a large dose of perindopril showing a normal spherical nucleus with intact regular walls and preserved nucleolus (N). The mitochondria are abundant with preserved cristae (Arrow) and the rough endoplasmic reticulum cisternae appear nearly normal with mild dilatation (Arrowhead).

Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

Techniques: Control, Disruption

Figure 13. The mechanisms by which perindopril mitigates methotrexate-induced hepatotoxicity (This artwork was constructed using Reactome icon library and Smart Art Servier items).

Journal: Pharmaceuticals

Article Title: Repositioning Perindopril for Mitigation of Methotrexate-Induced Hepatotoxicity in Rats

doi: 10.3390/ph18030358

Figure Lengend Snippet: Figure 13. The mechanisms by which perindopril mitigates methotrexate-induced hepatotoxicity (This artwork was constructed using Reactome icon library and Smart Art Servier items).

Article Snippet: Perindopril powder was supplied by Santa Cruz Biotechnology, Inc., Dallas, TX, USA (Catalog # sc205799A; CAS No. 82834-16-0).

Techniques: Construct

Basic characteristics of the included studies

Journal: European Journal of Medical Research

Article Title: Antihypertensive strategies for the prevention of secondary stroke: a systematic review and meta-analysis

doi: 10.1186/s40001-024-02226-3

Figure Lengend Snippet: Basic characteristics of the included studies

Article Snippet: Hasegawa et al. (2004) [ ] , RCT , Japan , 328/339 , 60 ± 9.0 , 244/84 , 254/85 , Perindopril , Placebo.

Techniques:

Review

Structured Review

Images

1) Product Images from "Immune cell uptake of glycinated nanoparticles conjugated to anti-fibrotic peptides enables their prolonged activity and oral administration"

Similar Products

Image Search Results